October 9, 2016
New Data on the Combination of Lilly’s ALIMTA and Merck’s KEYTRUDA
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Merck
March 10, 2016
Sanofi and MSD/Merck in joint vaccines operations in Europe
Sanofi and MSD/Merck in joint vaccines operations in Europe
November 19, 2015
Lilly and Merck move on with oncology clinical trial of and Keytruda
Eli Lilly and Merck are moving on with an existing oncology clinical trial collaboration to evaluate the safety and efficacy of the combination of Lilly’s Almita (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
October 8, 2015
Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
Merck KGaA and Pfizer have announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.
October 6, 2015
Merck: Results of Phase 3 Study of Investigational Chronic Hepatitis C Therapy
Merck has announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection.